Physician profile
Robert G Brown
NPI 1447242748
$21,557.14
in general payments reported to CMS, 2019-2025
31 companies · $4,367 in 2025
The $4,367 reported for 2025 was more than what 87% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,985 · 2020: $1,420 · 2021: $2,387 · 2022: $3,556 · 2023: $3,479 · 2024: $4,362 · 2025: $4,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,200.13 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,009.32 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,478.98 | 2019-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $1,972.85 | 2019-2025 | |
| Leo Pharma INC. | $1,423.70 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $1,248.55 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,238.60 | 2019-2025 | |
| Lilly USA, LLC | $1,152.69 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Ucb, INC. | $974.53 | 2021-2025 | Bimzelx |
| Amgen INC. | $788.15 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $782.83 | 2019-2025 | Ilumya |
| Galderma Laboratories, L.P. | $666.68 | 2019-2025 | Nemluvio, Aklief, Oracea |
| E.R. Squibb & Sons, L.L.C. | $647.60 | 2022-2025 | Sotyktu |
| Pfizer INC. | $617.04 | 2019-2025 | |
| Incyte Corporation | $587.67 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $329.06 | 2022-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $298.02 | 2019-2025 | Seysara, Klisyri |
| Arcutis Biotherapeutics, INC. | $258.16 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $251.91 | 2020-2022 | |
| Organon LLC | $151.15 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.31 | 2023-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.75 | 2019-2025 | Jublia, Cabtreo |
| Mayne Pharma Commercial LLC | $105.55 | 2019-2023 | |
| Biofrontera INC. | $65.37 | 2022-2025 | Ameluz |
| Botanix Sb INC | $54.32 | 2025 | Sofdra |
| Lnhc, INC | $48.19 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $45.35 | 2024-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $41.45 | 2021 | |
| Dermira, INC. | $21.66 | 2019 | |
| Vyne Pharmaceuticals INC. | $20.66 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.40 | 2023 | Seglentis |
| Strata Skin Sciences, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.